Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

China Local BRCA Testing and Exploration of Ovarian Cancer Treatment Outcomes of Different BRCA Status in Newly Diagnosed Epithelial Ovarian Cancer Patients

NCT03203993 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT03203993
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03203993 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
China Local BRCA Testing and Exploration of Ovarian Cancer Treatment Outcomes of Different BRCA Status in Newly Diagnosed Epithelial Ovarian Cancer Patients
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Terminated
Start date
January 31, 2018
Completion date
March 31, 2020
Enrollment
29 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian cancer